Dennis Henner, Ph.D., has been Managing Director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 27 years of direct industry and investment experience within the healthcare sector. From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech’s executive committee.
Dr. Henner received his Ph.D. from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Dr. Henner represents Clarus Ventures on the Board of Directors of Aerie (NASDAQ: AERI), Cleave, CoMentis, and Proactive. In addition he is a member of the Board of Trustees of Reed College.
Previous directorships include Celebrant, Coregent, Inc. (acquired by Sangamon Biosciences), Ferritin Biosciences (acquired by Shire), Kilobits, Pelican Technologies, Renato (acquired by Pfizer), Rigel (NASDAQ:RIGL), SARCode (acquired by Shire), Synergia, and Tercica (acquired by Ipsen).